JP5899243B2 - ドネペジル経皮吸収型パッチ - Google Patents
ドネペジル経皮吸収型パッチ Download PDFInfo
- Publication number
- JP5899243B2 JP5899243B2 JP2013549552A JP2013549552A JP5899243B2 JP 5899243 B2 JP5899243 B2 JP 5899243B2 JP 2013549552 A JP2013549552 A JP 2013549552A JP 2013549552 A JP2013549552 A JP 2013549552A JP 5899243 B2 JP5899243 B2 JP 5899243B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- acrylate
- transdermal patch
- sensitive adhesive
- pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 title claims description 137
- 229960003530 donepezil Drugs 0.000 title claims description 68
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 32
- 239000011159 matrix material Substances 0.000 claims description 23
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 claims description 15
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 15
- 229920001577 copolymer Polymers 0.000 claims description 13
- 239000012458 free base Substances 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 239000000178 monomer Substances 0.000 claims description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 8
- -1 methyl hydroxymethyl Chemical group 0.000 claims description 8
- 239000003961 penetration enhancing agent Substances 0.000 claims description 7
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims description 2
- IEVADDDOVGMCSI-UHFFFAOYSA-N 2-hydroxybutyl 2-methylprop-2-enoate Chemical compound CCC(O)COC(=O)C(C)=C IEVADDDOVGMCSI-UHFFFAOYSA-N 0.000 claims description 2
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 2
- GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 claims description 2
- QZPSOSOOLFHYRR-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate Chemical compound OCCCOC(=O)C=C QZPSOSOOLFHYRR-UHFFFAOYSA-N 0.000 claims description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- NDWUBGAGUCISDV-UHFFFAOYSA-N 4-hydroxybutyl prop-2-enoate Chemical compound OCCCCOC(=O)C=C NDWUBGAGUCISDV-UHFFFAOYSA-N 0.000 claims description 2
- INRQKLGGIVSJRR-UHFFFAOYSA-N 5-hydroxypentyl prop-2-enoate Chemical compound OCCCCCOC(=O)C=C INRQKLGGIVSJRR-UHFFFAOYSA-N 0.000 claims description 2
- XFOFBPRPOAWWPA-UHFFFAOYSA-N 6-hydroxyhexyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCCCO XFOFBPRPOAWWPA-UHFFFAOYSA-N 0.000 claims description 2
- OCIFJWVZZUDMRL-UHFFFAOYSA-N 6-hydroxyhexyl prop-2-enoate Chemical compound OCCCCCCOC(=O)C=C OCIFJWVZZUDMRL-UHFFFAOYSA-N 0.000 claims description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 2
- ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 claims description 2
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 claims description 2
- GJIDOLBZYSCZRX-UHFFFAOYSA-N hydroxymethyl prop-2-enoate Chemical compound OCOC(=O)C=C GJIDOLBZYSCZRX-UHFFFAOYSA-N 0.000 claims description 2
- GYDSPAVLTMAXHT-UHFFFAOYSA-N pentyl 2-methylprop-2-enoate Chemical compound CCCCCOC(=O)C(C)=C GYDSPAVLTMAXHT-UHFFFAOYSA-N 0.000 claims 1
- 239000010410 layer Substances 0.000 description 26
- 210000003491 skin Anatomy 0.000 description 26
- 238000012360 testing method Methods 0.000 description 15
- 208000024827 Alzheimer disease Diseases 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 238000004088 simulation Methods 0.000 description 5
- 231100000245 skin permeability Toxicity 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 description 4
- 239000005020 polyethylene terephthalate Substances 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 239000012756 surface treatment agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960003135 donepezil hydrochloride Drugs 0.000 description 2
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical group CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- YGTVWCBFJAVSMS-UHFFFAOYSA-N 5-hydroxypentyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCCO YGTVWCBFJAVSMS-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 208000013677 cerebrovascular dementia Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
(b)感圧粘着性マトリクス層と、
を含み、該感圧粘着性マトリクス層は、
(i)ドネペジル遊離塩基と、
(ii)2−エチルヘキシルアクリレートおよび酢酸ビニルの共重合体と、2−エチルヘキシルアクリレート、酢酸ビニル、および、ヒドロキシル基含有モノマーの共重合体と、からなる群から選択されるアクリレート感圧粘着剤と、
(iii)乳酸ラウリル、イソプロピルミリステート、および、オレイン酸アルコールからなる群から選択される透過促進剤と、
を含み、
共重合体の総重量に対し、65〜75重量%の2−エチルヘキシルアクリレート、25〜35重量%の前記酢酸ビニル、および、0〜10重量%のヒドロキシル基含有モノマーが含まれ、
前記感圧粘着性マトリクス層の総重量に対し、1〜15%の前記ドネペジル遊離塩基、50〜99重量%の前記アクリレート感圧粘着剤、および、1〜10重量%の前記透過促進剤が含まれる。
[実施例]
1.サンプル:ドネペジル経皮吸収型パッチA1〜B1、B1〜B4、および、C1〜C5
2.試験方法および条件
(1)皮膚透過装置
皮膚を切断して予め決められた質量の大きさ、すなわち、1cm2のいくつかの断片とする。皮膚の断片を皮膚透過装置の隣り合うセルに対して位置決めする。隣り合うセルのジャケット内の温度は、摂氏32度に維持される。ドネペジル経皮吸収型パッチの剥離ライナーを剥がした後、皮膚の断片にマトリクス層をしっかり接着する。20重量%のポリエチレングリコール(PEG400)3.5mlを媒質としてセルに加える。適切な時間に、0.5mlの媒質を試験用に抽出し、さらに0.5mlの媒質をセルに加える。
(2)レセプター媒質:20重量%のポリエチレングリコール(PEG400)
(3)温度:摂氏32度
(4)サンプリング時間:24時間、48時間、および、72時間
(5)サンプル分析:サンプルは、クロマトグラフィ技術を用いて分析した。
3.結果
図1は、本発明の実施例および比較例におけるドネペジル経皮吸収型パッチの皮膚透過量と時間との関係を示す。図1および図2に示すように、72時間後には、サンプルA1、A2およびA3の皮膚透過量は、サンプルC1、C2、C3およびC4の皮膚透過量より大きくなる。サンプルA1〜A3については、サンプルA2の皮膚透過量が最高であり、サンプルA1が2番目に多く、サンプルA3は最低である。図2は、本発明の種々の透過促進剤を含む、または、含まないドネペジル経皮吸収型パッチの皮膚透過量と時間との関係を示す。図2に示すように、72時間後には、サンプルB1の皮膚透過量が最高になり、サンプルB2およびB3が2番目に多く、サンプルC5は3番目に多く、サンプルB4が最低である。換言すると、サンプルB1は、他の全てのサンプルよりも高い皮膚透過性を有する。透過促進剤およびその種の使用と、経皮吸収型パッチの皮膚透過量とは関連性があるという結果が明らかになった。図3は、本発明のサンプルB1のドネペジル経皮吸収型パッチの皮膚透過量と時間との関係を示す。図3に示すように、本発明のドネペジル経皮吸収型パッチの皮膚透過量は、ほぼ48時間後にピークに達し、最大透過度は、時間当たり約8.03μg/cm2である。経皮吸収型パッチは、少なくとも3日間、それどころか7日間も継続的かつ安定して薬物活性を呈することができる。表3は、主成分と、本発明の経皮吸収型パッチの定常状態における皮膚透過結果(サンプルB1)と、米国特許公開公報第2010/0080842のドネペジル経皮吸収型パッチ(明細書の表1におけるサンプル4の製剤、および、表3におけるサンプル4の製剤(サンプルC6およびC7)とを示す。
Claims (11)
- (a)裏打ち層と、
(b)感圧粘着性マトリクス層とを含み、
前記感圧粘着性マトリクス層は、
(i)非結晶状のドネペジル遊離塩基と、
(ii)2−エチルヘキシルアクリレートおよび酢酸ビニルの共重合体と、2−エチルヘキシルアクリレート、酢酸ビニル、および、ヒドロキシル基含有モノマーの共重合体と、からなる群から選択されるアクリレート感圧粘着剤と、
(iii)乳酸ラウリル、イソプロピルミリステート、および、オレイン酸アルコールからなる群から選択される透過促進剤と、
のみからなり、
前記共重合体の総重量に対し、65〜75重量%の前記2−エチルヘキシルアクリレート、25〜35重量%の前記酢酸ビニル、および、0〜10重量%の前記ヒドロキシル基含有モノマーが含まれ、
前記感圧粘着性マトリクス層の総重量に対し、1〜15重量%の前記ドネペジル遊離塩基、50〜95重量%の前記アクリレート感圧粘着剤、および、1〜10重量%の前記透過促進剤が含まれる、
ドネペジル経皮吸収型パッチ。 - 前記感圧粘着性マトリクス層の総重量に対し、5〜12重量%の前記ドネペジル遊離塩基が含まれている、請求項1に記載の経皮吸収型パッチ。
- 前記アクリレート感圧粘着剤は、約72重量%の2−エチルヘキシルアクリレートと、約28重量%の酢酸ビニルとの共重合体である、請求項1に記載の経皮吸収型パッチ。
- 前記アクリレート感圧粘着剤は、約70重量%の2−エチルヘキシルアクリレートと、約30重量%の酢酸ビニルとの共重合体である、請求項1に記載の経皮吸収型パッチ。
- 前記アクリレート感圧粘着剤は、約67重量%の2−エチルヘキシルアクリレートと、約28重量%の酢酸ビニルと、約5重量%のヒドロキシル基含有モノマーとの共重合体である、請求項1に記載の経皮吸収型パッチ。
- 前記ヒドロキシル基含有モノマーは、ヒドロキシメチルアクリレート、メチルヒドロキシメチルアクリレート(methyl hydroxymethyl acrylate)、ヒドロキシエチルアクリレート、ヒドロキシエチルメタクリレート、ヒドロキシプロピルアクリレート、ヒドロキシプロピルメタクリレート、ヒドロキシブチルアクリレート、ヒドロキシブチルメタクリレート、ヒドロキシペンチルアクリレート、ヒドロキシペンチルメタクリレート、ヒドロキシヘキシルアクリレート、および、ヒドロキシヘキシルメタクリレートからなる群から選択される、請求項5に記載の経皮吸収型パッチ。
- 前記感圧粘着性マトリクス層の総重量に対し、80〜95重量%の前記アクリレート感圧粘着剤が含まれる、請求項1に記載の経皮吸収型パッチ。
- 前記感圧粘着性マトリクス層の総重量に対し、3〜6重量%の前記透過促進剤が含まれる、請求項1に記載の経皮吸収型パッチ。
- 剥離ライナーをさらに含む、請求項1に記載の経皮吸収型パッチ。
- 前記剥離ライナーは、分割線を有する、請求項9に記載の経皮吸収型パッチ。
- 前記分割線は、直線または曲線である、請求項10に記載の経皮吸収型パッチ。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW100101169A TWI433904B (zh) | 2011-01-12 | 2011-01-12 | 多奈哌齊經皮貼片 |
TW100101169 | 2011-01-12 | ||
PCT/US2012/021145 WO2012097197A1 (en) | 2011-01-12 | 2012-01-12 | Donepezil transdermal patch |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014502639A JP2014502639A (ja) | 2014-02-03 |
JP5899243B2 true JP5899243B2 (ja) | 2016-04-06 |
Family
ID=46469021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013549552A Active JP5899243B2 (ja) | 2011-01-12 | 2012-01-12 | ドネペジル経皮吸収型パッチ |
Country Status (7)
Country | Link |
---|---|
US (1) | US20140052081A1 (ja) |
EP (1) | EP2663296B1 (ja) |
JP (1) | JP5899243B2 (ja) |
KR (1) | KR101617927B1 (ja) |
CN (1) | CN102579409B (ja) |
TW (1) | TWI433904B (ja) |
WO (1) | WO2012097197A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015028291A2 (pt) * | 2013-05-10 | 2017-07-25 | Ctc Bio Inc | filme contendo base livre de donepezil e método para a preparação do mesmo. |
WO2015054058A1 (en) * | 2013-10-07 | 2015-04-16 | Teikoku Pharma Usa, Inc. | Dexmedetomidine Transdermal Delivery Devices and Methods for Using the Same |
US10987342B2 (en) | 2013-10-07 | 2021-04-27 | Teikoku Pharma Usa, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
ES2856189T3 (es) | 2013-10-07 | 2021-09-27 | Teikoku Pharma Usa Inc | Métodos y composiciones para el tratamiento del trastorno de hiperactividad por déficit de atención, ansiedad e insomnio utilizando composiciones transdérmicas de dexmedetomidina |
KR101485822B1 (ko) * | 2014-01-22 | 2015-01-23 | 주식회사 대웅제약 | 도네페질 또는 그의 염을 함유하는 경피흡수제제 |
CN113797180A (zh) * | 2014-12-18 | 2021-12-17 | Icure药品株式会社 | 含有多奈哌齐为有效成分的经皮吸收制剂 |
WO2016190002A1 (ja) * | 2015-05-26 | 2016-12-01 | ニプロ株式会社 | 貼付剤 |
EP3310348B1 (en) * | 2015-06-22 | 2020-08-05 | Corium, Inc. | Transdermal adhesive composition comprising a poorly soluble therapeutic agent |
IL260290B2 (en) | 2015-12-30 | 2023-11-01 | Corium Inc | Systems and methods for long-term percutaneous administration |
CN105769826A (zh) * | 2016-02-03 | 2016-07-20 | 林晓云 | 与人体皮肤肌肉组织运动相吻合的膏贴 |
KR102419767B1 (ko) * | 2016-06-23 | 2022-07-12 | 코리움, 인크. | 친수성 및 소수성 도메인 및 치료제가 포함된 접착성 매트릭스 |
EP3490540A1 (en) * | 2016-07-27 | 2019-06-05 | Corium International, Inc. | Sodium bicarbonatein situ |
CN109789134A (zh) | 2016-07-27 | 2019-05-21 | 考里安国际公司 | 与口服递送药代动力学生物等效的透皮递送系统 |
CA3032103A1 (en) | 2016-07-27 | 2018-02-01 | Corium International, Inc. | Memantine transdermal delivery systems |
CA3086163A1 (en) | 2017-12-20 | 2019-06-27 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
CN113164392A (zh) * | 2018-11-26 | 2021-07-23 | 益霸生物公司 | 多奈哌齐共熔混合物及其用途 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU718096C (en) * | 1995-06-07 | 2001-11-22 | Noven Pharmaceuticals, Inc. | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
US7150881B2 (en) * | 1997-06-26 | 2006-12-19 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
WO2001032115A1 (en) * | 1999-11-04 | 2001-05-10 | Xel Herbaceuticals | Transdermal administration of huperzine |
US20040258741A1 (en) * | 2001-10-17 | 2004-12-23 | Takaaki Terahara | Percutaneous absorption preparations |
CA2560840C (en) * | 2004-03-24 | 2014-05-06 | Corium International, Inc. | Transdermal delivery device |
CN101232875B (zh) * | 2005-06-10 | 2014-06-25 | 3M创新有限公司 | 处理粘合层叠片片段的方法 |
JP4950510B2 (ja) * | 2006-02-16 | 2012-06-13 | 久光製薬株式会社 | 経皮吸収製剤 |
RU2428179C2 (ru) * | 2006-05-08 | 2011-09-10 | Тейкоку Сейяку Ко., Лтд. | Препаративные формы лекарственных средств против слабоумия для чрескожного введения |
JP5097359B2 (ja) * | 2006-05-09 | 2012-12-12 | 久光製薬株式会社 | ドネペジル経皮吸収型製剤 |
JP5005277B2 (ja) * | 2006-07-13 | 2012-08-22 | 日東電工株式会社 | 貼付剤および貼付製剤 |
WO2008044336A1 (fr) * | 2006-10-11 | 2008-04-17 | Hisamitsu Pharmaceutical Co., Inc. | Préparation adhésive contenant un cristal |
JP2009031537A (ja) * | 2007-07-27 | 2009-02-12 | Seiko Epson Corp | 光学素子およびその製造方法、液晶装置、ならびに電子機器 |
KR101454362B1 (ko) * | 2008-03-24 | 2014-10-23 | 아이큐어 주식회사 | 도네페질을 유효성분으로 함유하는 치매 치료용경피흡수제제 |
US20090291127A1 (en) * | 2008-05-21 | 2009-11-26 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
KR20110011650A (ko) * | 2008-05-30 | 2011-02-08 | 닛토덴코 가부시키가이샤 | 도네페질 함유 부착 제제 및 그 포장체 |
US20090297591A1 (en) * | 2008-05-30 | 2009-12-03 | Orient Pharma Co., Ltd. | Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds |
US20100080842A1 (en) * | 2008-09-30 | 2010-04-01 | Jianye Wen | Transdermal extended-delivery donepezil compositions and methods for using the same |
EP2491931B1 (en) * | 2009-10-21 | 2017-09-20 | Teikoku Seiyaku Co., Ltd. | Transdermally absorbable donepezil-containing preparation |
ES2547888T3 (es) * | 2010-04-28 | 2015-10-09 | Hisamitsu Pharmaceutical Co., Inc. | Preparación que contiene donepezilo absorbible por vía transdérmica |
NZ605352A (en) * | 2010-06-30 | 2013-10-25 | Nal Pharmaceuticals Ltd | Process for producing glycosaminoglycans |
-
2011
- 2011-01-12 TW TW100101169A patent/TWI433904B/zh active
-
2012
- 2012-01-10 CN CN2012100228714A patent/CN102579409B/zh active Active
- 2012-01-12 US US13/979,579 patent/US20140052081A1/en not_active Abandoned
- 2012-01-12 WO PCT/US2012/021145 patent/WO2012097197A1/en active Application Filing
- 2012-01-12 EP EP12734524.7A patent/EP2663296B1/en active Active
- 2012-01-12 KR KR1020137018245A patent/KR101617927B1/ko active IP Right Grant
- 2012-01-12 JP JP2013549552A patent/JP5899243B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP2663296B1 (en) | 2017-05-17 |
CN102579409B (zh) | 2013-10-16 |
US20140052081A1 (en) | 2014-02-20 |
TW201229170A (en) | 2012-07-16 |
EP2663296A1 (en) | 2013-11-20 |
WO2012097197A1 (en) | 2012-07-19 |
JP2014502639A (ja) | 2014-02-03 |
CN102579409A (zh) | 2012-07-18 |
KR20130121139A (ko) | 2013-11-05 |
EP2663296A4 (en) | 2014-10-01 |
KR101617927B1 (ko) | 2016-05-03 |
TWI433904B (zh) | 2014-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5899243B2 (ja) | ドネペジル経皮吸収型パッチ | |
JP5122445B2 (ja) | 抗認知症薬物の経皮吸収製剤 | |
CN109789133A (zh) | 多奈哌齐透皮递送系统 | |
US20100080842A1 (en) | Transdermal extended-delivery donepezil compositions and methods for using the same | |
CN107468673A (zh) | 透皮施用美金刚 | |
JP2020503381A (ja) | アセナピンを含有する経皮治療システム | |
JP5795264B2 (ja) | 抗認知症薬物の経皮吸収製剤 | |
TWI341735B (en) | Adhesive preparations | |
US20100178307A1 (en) | Transdermal anti-dementia active agent formulations and methods for using the same | |
JP5925903B2 (ja) | 貼付剤 | |
TW201210636A (en) | Medical patch | |
JP2022190070A (ja) | 貼付剤 | |
CN101961418B (zh) | 一种双控释高剂量低刺激性的辣椒碱复方透皮贴剂 | |
JP6129632B2 (ja) | 貼付剤 | |
JP3980634B2 (ja) | 活性物質モルフィン−6−グルクロニドを含む全身的経皮投与用医薬組成物 | |
WO2018199018A1 (ja) | 経皮吸収型製剤およびその製造方法 | |
US20040197397A1 (en) | Drug delivery system for treatment of urinary incontinence | |
TW201143817A (en) | Transdermally absorbed preparation of anti-dementia drug | |
JP6864968B2 (ja) | 貼付剤 | |
JP2018528175A (ja) | 経皮送達系 | |
KR20150057134A (ko) | 손발톱진균증 치료를 위한 테르비나핀-함유 경피흡수제제 | |
MX2008014151A (es) | Preparaciones de absorcion percutanea de drogas contra demencia. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130918 Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131004 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130918 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20131003 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140916 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141202 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141209 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150114 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150313 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151218 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20151225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160209 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160307 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5899243 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |